These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19949039)

  • 21. Case report of interstitial nephritis induced by bevacizumab therapy for glioblastoma multiforme.
    Lomax AJ; Hill PA; Ashley DM
    J Oncol Pharm Pract; 2013 Dec; 19(4):365-8. PubMed ID: 23235917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bevacizumab and recurrent malignant gliomas: a European perspective.
    Wick W; Weller M; van den Bent M; Stupp R
    J Clin Oncol; 2010 Apr; 28(12):e188-9; author reply e190-2. PubMed ID: 20159801
    [No Abstract]   [Full Text] [Related]  

  • 23. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence.
    Chamberlain MC
    Neurology; 2009 Feb; 72(8):772-3; author reply 773-4. PubMed ID: 19237713
    [No Abstract]   [Full Text] [Related]  

  • 24. Salvage therapy with single agent bevacizumab for recurrent glioblastoma.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2010 Jan; 96(2):259-69. PubMed ID: 19593660
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab: in previously treated glioblastoma.
    Moen MD
    Drugs; 2010; 70(2):181-9. PubMed ID: 20108991
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bevacizumab for newly diagnosed glioblastoma.
    Gilbert MR; Sulman EP; Mehta MP
    N Engl J Med; 2014 May; 370(21):2048-9. PubMed ID: 24849088
    [No Abstract]   [Full Text] [Related]  

  • 27. Arterial hypertension and bevacizumab treatment in glioblastoma: no correlation with clinical outcome.
    Wick A; Schäfer N; Dörner N; Schemmer D; Platten M; Bendszus M; Wick W
    J Neurooncol; 2010 Mar; 97(1):157-8. PubMed ID: 19727565
    [No Abstract]   [Full Text] [Related]  

  • 28. Bevacizumab for newly diagnosed glioblastoma.
    Chinot OL; Wick W; Cloughesy T
    N Engl J Med; 2014 May; 370(21):2049. PubMed ID: 24860870
    [No Abstract]   [Full Text] [Related]  

  • 29. Bevacizumab for newly diagnosed glioblastoma.
    Haines IE; Gabor Miklos GL
    N Engl J Med; 2014 May; 370(21):2048. PubMed ID: 24849089
    [No Abstract]   [Full Text] [Related]  

  • 30. Mechanisms of evasion to antiangiogenic therapy in glioblastoma.
    Rose SD; Aghi MK
    Clin Neurosurg; 2010; 57():123-8. PubMed ID: 21280504
    [No Abstract]   [Full Text] [Related]  

  • 31. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical Impact of Bevacizumab in Patients with Relapsed Glioblastoma: Focus on a Real-Life Monocentric SurVey (SV1 Study).
    Rivoirard R; Chargari C; Guy JB; Nuti C; Peoc'h M; Forest F; Falk AT; Garin C; Adjabi A; Hoarau D; Fotso MJ; Langrand Escure J; Moriceau G; Fournel P; Boutet C; Magné N
    Chemotherapy; 2016; 61(5):269-74. PubMed ID: 27057742
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bevacizumab for glioblastoma multiforme after traumatic subarachnoid hemorrhage.
    Lukas RV; Goldenberg F; Nicholas MK
    J Clin Neurosci; 2012 Sep; 19(9):1310-1. PubMed ID: 22721885
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predicting glioblastoma response to bevacizumab through marker profiling?
    Kessler T
    Neuro Oncol; 2016 Feb; 18(2):149-50. PubMed ID: 26803809
    [No Abstract]   [Full Text] [Related]  

  • 35. Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?
    D'Alessandris QG; Capo G; Pallini R
    Neuro Oncol; 2014 Oct; 16(10):1427. PubMed ID: 25053854
    [No Abstract]   [Full Text] [Related]  

  • 36. 10 Questions about the use of bevacizumab in the management of recurrent malignant gliomas.
    Chamberlain MC
    Neurologist; 2010 Jan; 16(1):56-60. PubMed ID: 20065801
    [No Abstract]   [Full Text] [Related]  

  • 37. Treatment of glioblastoma with bevacizumab: has a new standard therapy been defined?
    Chamberlain MC
    CNS Drugs; 2011 Oct; 25(10):815-8. PubMed ID: 21936584
    [No Abstract]   [Full Text] [Related]  

  • 38. Avastin: more questions than answers. .
    Desjardins A; Sampson JH
    J Neurosurg; 2012 Feb; 116(2):336-40; discussion 340. PubMed ID: 22035270
    [No Abstract]   [Full Text] [Related]  

  • 39. Unexpected late radiation neurotoxicity following bevacizumab use: a case series.
    Kelly PJ; Dinkin MJ; Drappatz J; O'Regan KN; Weiss SE
    J Neurooncol; 2011 May; 102(3):485-90. PubMed ID: 20680396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab as secondline treatment of glioblastoma -  worth the effort?
    Rovere RK
    Klin Onkol; 2014; 27(3):219-20. PubMed ID: 24918282
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.